SAI LIFE SCIENCES LIMITED
Momentum (90/100) does the heavy lifting; valuation (0/100) is the drag.
ExpensiveOvervaluedStocksWizard rates SAI LIFE SCIENCES LIMITED a Hold, scoring 45/100 on our blended model. At ₹1,315.1 it trades above our blended DCF and relative-multiples fair value of ₹657.55, about 50% downside to that estimate — we read it as overvalued by 50%. On 75.3x trailing earnings it sits pricier than the Healthcare median of about 37.6x. It's trading right at its 52-week high of ₹1,315.9. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 5/9. The average analyst target of ₹1,275 implies about 3% downside across 6 analysts. It clears 8 of 13 investability checks, with durability 69, valuation 0 and momentum 90 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹526.04.
Analyst views
1-year price
EOD · 2026-07-3152-week range
-0.06% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Hold45Piotroski F-score 5/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Pass: ROE above 15%: 15.1%
- Pass: Low debt (D/E < 0.5): 0.12x
- Fail: Positive free cash flow
- Fail: Revenue growth > 10%: 4%
- Pass: Earnings growing: 18%
- Pass: Net margin ≥ 10%: 15.9%
- Pass: Current ratio > 1.5: 1.69
- Fail: Below our fair value
- Fail: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 14.82
- Fail: Piotroski ≥ 7: 5/9
Quarterly results
Annual financials
Shareholding
- Promoter38.0%
- Institutions42.6%
- Public & other19.4%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Lightly leveraged balance sheet.
- Healthy profit margin (15.9%).
- Trading near its 52-week high.
- Financially solid — Altman Z 14.82.
Opportunities
- Earnings growing (18% YoY).
Bear case
Threats
- Rich valuation versus sector peers.
- Trades ~50% above our estimated fair value.
About SAI LIFE SCIENCES LIMITED
Sai Life Sciences Limited is a contract research, development, and manufacturing organization operating in India and internationally. The company offers medicinal chemistry, pharmacokinetics, manufacturing, and contract development services. Formerly known as SAI Advantium Pharma Limited, it adopted its current name in July 2006.
SAI LIFE SCIENCES LIMITED — frequently asked questions
Is SAI LIFE SCIENCES LIMITED a buy, hold or sell?
StocksWizard currently rates SAI LIFE SCIENCES LIMITED (SAILIFE) a Hold, based on a blended score of 45/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is SAI LIFE SCIENCES LIMITED's fair value?
Our blended DCF and relative-valuation model estimates SAI LIFE SCIENCES LIMITED's fair value at about ₹657.55, versus a current price of ₹1,315.1 — roughly 50% downside. On that basis the stock looks overvalued by 50%.
Is SAI LIFE SCIENCES LIMITED financially healthy?
SAI LIFE SCIENCES LIMITED scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 5/9.
How has SAI LIFE SCIENCES LIMITED's share price performed?
SAI LIFE SCIENCES LIMITED is up 22% over three months, and last traded at ₹1,315.1. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.